SFDA Issues Labeling Revision On NSAlDs
This article was originally published in PharmAsia News
Executive SummaryChina's State FDA has issued a notice on the prescribing information of nonsteroid anti-inflammatory drugs, demanding that drug manufacturers revise their drug prescribing information and labels, and notify relevant medical institutions and drug-handling enterprises of the amended content. Drug manufacturers have to track clinical safety information on their NSAlDs, monitor adverse drug reactions and report such incidents to authorities. The new supplementary information in the notice focuses on the possibility of NSAlDs causing cerebral, cardiovascular and gastrointestinal bleeding. The sales of NSAIDs, anti-inflammatory drugs and antirheumatic agents have dropped in China following adverse events linked to Vioxx. The latest revision may prove challenging for the industry but experts believe the market will grow due to the large pool of patients and stepped-up new drug launches. (Click here for more - Chinese Language)
You may also be interested in...
ConMed’s ambitions in orthopedics are to be the clinician’s support, develop differentiated offerings and avoid “me too” activity, before all notions of leading the market rankings.
Executives On The Move: Tech And Science Announcements At Orexo And Agios, And Board Changes At Accorda And RhoVac
Swedish pharma Orexo welcomes EVP, digital health and anti-cancer therapeutics firm Agios Pharmaceuticals announces Bristol-Myers Squibb exec as its next CSO. And a chair takes a seat at Accorda Therapeutics and RhoVac.
In 2018, the top 100 publicly listed and reportable medical device technology companies had global sales spanning from over $30bn to some $100m in the lower reaches. As the latest In Vivo Medtech 100 ranking shows, many of the major changes in value sales were linked to company restructurings. But there were some impressive organic gains too.